Aligos Therapeutics Advances “Compelling Potential Treatment Option” in MASH
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has completed enrollment in a Phase 2a clinical study for a metabolic dysfunction-associated steatohepatitis (MASH) therapeutic, with topline safety and efficacy data anticipated in early Q4 2024. The company is evaluating ALG-055009, a best-in-class thyroid hormone receptor beta (THR-ß) agonist, which has demonstrated safety and efficacy in a Phase 1 trial.
Aligos’ trial is a randomized, double-blind, placebo-controlled trial that has enrolled approximately 100 subjects with presumed MASH and stage 1-3 liver fibrosis.
“Completing enrollment in our first Phase 2a trial is a tremendous accomplishment for the Aligos team,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
Aligos also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study. Dr. Loomba is the Chief of the Division of Gastroenterology and Hepatology and Professor of Medicine at the University of California, San Diego (UCSD). He is also the Director of the UCSD NAFLD Research Center.
“I’d like to welcome Dr. Rohit Loomba as our Principal Investigator for the HERALD study,” said Dr. Blatt. “Dr. Loomba has a broad track record of contributions to the MASH field, having pioneered the use of MRI-PDFF as a noninvasive test to assess liver steatosis. We look forward to his insights and contributions to the HERALD study and beyond.”
MASH, an accumulation of fatty deposits in the liver, affects approximately 30% of the worldwide population.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
